Noxopharm Limited
NOXOF · OTC
6/30/2024 | 12/30/2023 | 6/30/2023 | 12/30/2022 | |
|---|---|---|---|---|
| Market Cap | $20 | $19 | $13 | $56 |
| - Cash | $2 | $5 | $3 | $11 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $17 | $14 | $10 | $45 |
| Revenue | $2 | $1 | $1 | $2 |
| % Growth | 196.1% | -54.5% | -20.4% | – |
| Gross Profit | -$1 | $1 | -$1 | -$1 |
| % Margin | -63.5% | 99.9% | -82.1% | -73.2% |
| EBITDA | -$3 | -$1 | -$3 | -$3 |
| % Margin | -193.4% | -186.3% | -188.2% | -163.7% |
| Net Income | -$1 | -$2 | -$5 | -$3 |
| % Margin | -60.2% | -412.2% | -361.4% | -162.2% |
| EPS Diluted | -0.004 | -0.009 | -0.017 | -0.009 |
| % Growth | 56.5% | 48.5% | -77.4% | – |
| Operating Cash Flow | -$3 | $2 | -$8 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | $2 | -$8 | -$1 |